4-Chlorobenzo[b]thiophene CAS 66490-33-3 Purity >98.0% (GC) Brexpiprazole Intermediate Factory

Short Description:

Chemical Name: 4-Chlorobenzo[b]thiophene

CAS: 66490-33-3

Purity: >98.0% (GC)

Appearance: Colorless Liquid

Intermediate of Brexpiprazole (CAS: 913611-97-9)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Chemical Name	4-Chlorobenzo[b]thiophene
Synonyms	4-Chloro-Benzo[b]thiophene; 4-Chloro-1-Benzothiophene; 4-Chlorobenzothiophene
CAS Number	66490-33-3
CAT Number	RF-PI1983
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C8H5ClS
Molecular Weight	168.64
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Colorless Liquid
Purity / Analysis Method	>98.0% (GC)
Total Impurities	<2.00%
Infrared Spectrum	Conforms to Structure
NMR	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate of Brexpiprazole (CAS: 913611-97-9)

Package & Storage:

Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

4-Chlorobenzo[b]thiophene (CAS: 66490-33-3) is an Intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole is a novel antipsychotic drug which serves as a serotonin ® dopamine activity modulator and has demonstrated efficacy as an adjunctive treatment in patients with major depressive disorder (MDD). The drug exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT1A and dopamine D2 receptors and as a full antagonist of 5-HT2A and noradrenaline α1B/2C receptors, with similar subnanomolar binding affinity. The drug, which was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression. Brexpiprazole is widely considered to be a successor to Otsuka’s antipsychotic drug aripiprazole (trade name Abilify) whose patent expired in August 2014.